Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P636: Long-term outcome of anti-tumour necrosis factor treatment in inflammatory bowel disease: A real-life observational study at Østfold Central Hospital, NorwayECCO '18 Vienna
Year: 2018
Authors:

F. Lerang1*, E. Gunther2, M. Henriksen1, L.-P. Jelsness-Jørgensen1,3

1Central Hospital of Østfold, Medical, Sarpsborg, Norway, 2Nedre Glommen Legegruppe, Medical, Fredrikstad, Norway, 3Østfold University College, Fredrikstad, Norway

P637: High faecal and serum tumour necrosis factor-α levels are associated with non-response to infliximab in patients with ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

H. Meringer1,2,3*, N. Maharshak1,2,3, Y. Ron1,3, H. Yanai1,3,4, S. Cohen-Kedar1,2,3,4, I. Dotan1,2,3,4

1Tel Aviv Sourasky Medical Center, Inflammatory Bowel Diseases Center, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel, 2Tel Aviv Sourasky Medical Center, Research Center for Digestive Tract and Liver Diseases, Tel Aviv, Israel, 3Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel, 4Current: Rabin Medical Center, Department of Gastroenterology, Petach Tikva, Israel

P638: Nutritional status in paediatric Crohn’s disease patients: Does exclusive enteral nutrition help?ECCO '18 Vienna
Year: 2018
Authors:

C. Strisciuglio1*, E. Scarpato2, M.R. Serra2, F.P. Giugliano2, S. Cenni2, C. Mainolfi3, M. Martinelli2, E. Miele2

1University of the Campania “Luigi Vanvitelli”, Department of Woman, Child and General and Specialized Surgery, Naples, Italy, 2University of Naples “Federico II”, Department of Translational Medical Science, Section of Pediatrics, Naples, Italy, 3University of Naples “Federico II”, Department of Radiology, Naples, Italy

P639: Validation of the Quantum Blue® infliximab-level rapid test in clinical practice of patients with inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

A. Strik1*, T. Schuster2, M. Löwenberg1, C. Ponsioen1, G. D'Haens1

1Academic Medical Center, Gastroenterology and Hepatology, Amsterdam, The Netherlands, 2Buhlmann Laboratories, Schönenbuch, Switzerland

P640: Risk of post-operative complications among Crohn’s disease patients treated pre-operatively with vedolizumab. A matched case–control studyECCO '18 Vienna
Year: 2018
Authors:

J.Y. Kim1, K. Zaghiyan2, P. Fleshner2*

1Hallym University College of Medicine, Dongtan Sacred Hospital, Department of Surgery, KyungKee, Seoul, South Korea, 2Cedars-Sinai Medical Center, Division of Colorectal Surgery, Los Angeles, USA

P641: Comparison of rectal and oral mesalazine for treatment of rectal ulcerative proctitis: A prospective randomised clinical trial (CORRECT study)ECCO '18 Vienna
Year: 2018
Authors:

S. Kato1*, K. Kani1, H. Kurihara2, T. Ohmori3, K. Yakabi1

1Saitama Medical Center, Saitama Medical University, Department of Gastroenterology and Hepatology, Kawagoe City, Saitama, Japan, 2Tokorozawa Proctology Hospital, Tokorozawa, City, Saitama, Japan, 3Ohmori Toshihide Gastrointestinal Clinic, Ageo City, Saitama, Japan

P642: Adaptive dosing during infliximab induction therapy can improve mucosal healing rates in patients with ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

E. Dreesen1*, R. Faelens1, G. Van Assche2,3, M. Ferrante2,3, S. Vermeire2,3, A. Gils1, T. Bouillon1

1KU Leuven, Departement of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, 2University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 3KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium

P643: Filgotinib decreases systemic and mucosal markers of inflammation that are associated with endoscopic improvement in moderately to severely active Crohn’s disease patientsECCO '18 Vienna
Year: 2018
Authors:

X. Roblin1*, G. D'Haens2, R. Galien3, L. Goyal4, W. Li4, A. Mirza4, A. Serone4, C. Tasset5, A. Van der Aa5, J. Woo4, S. Vermeire6

1University Hospital, Saint-Etienne, France, 2Academic Medical Centre, Amsterdam, The Netherlands, 3Galapagos SASU, Romanville, France, 4Gilead Sciences, Foster City, USA, 5Galapagos NV, Mechelen, Belgium, 6University Hospitals Leuven, Leuven, Belgium

P644: Effectiveness of vedolizumab on intestinal outcomes and articular manifestations: Real-world data from the Sicilian Network for inflammatory bowel disease (SN-IBD)ECCO '18 Vienna
Year: 2018
Authors:

F.S. Macaluso1*, R. Orlando1, W. Fries2, M. Scolaro2, A. Magnano3, D. Pluchino3, M. Cappello4, G.C. Morreale4, S. Siringo5, A.C. Privitera6, C. Ferracane6, N. Belluardo7, N. Alberghina7, M. Ventimiglia1, G. Rizzuto1, S. Renna1, M. Cottone1, A. Orlando1, Sicilian Network for Inflammatory Bowel Disease (SN-IBD)

1Division of Internal Medicine, ''Villa Sofia-Cervello'' Hospital, Palermo, Italy, 2Inflammatory Bowel Disease Unit, A.O.U. Policlinico "G. Martino”, Messina, Italy, 3Gastroenterology Unit, A.O.U. Policlinico “Vittorio Emanuele”, Catania, Italy, 4Gastroenterology and Hepatology Unit, A.O.U. Policlinico “G. Giaccone”, Palermo, Italy, 5Gastroenterology Unit, A.R.N.A.S. “Garibaldi”, Catania, Italy, 6IBD Unit, A.O. "Cannizzaro”, Catania, Italy, 7Gastroenterology Unit, A.O. “Guzzardi”, Vittoria, Italy

P645: Dynamics of proinflammatory cytokines in patients with Crohn's disease who received combined therapy with mesenchymal stromal cells of bone marrow and azathioprineECCO '18 Vienna
Year: 2018
Authors:

O. Knyazev, N. Fadeeva*, A. Babayan, E. Dobroluybova, I. Donchenko

Moscow Clinical Research Center, Department of Inflammatory Bowel Disease, Moscow, Russian Federation

P646: Refinement of surgical technique offsets increased severity of Crohn’s disease and co-morbidities to maintain low post-operative morbidityECCO '18 Vienna
Year: 2018
Authors:

D. Mege1,2*, K. Garrett1, J. Milsom1, T. Sonoda1, F. Michelassi1

1New York Presbyterian Hospital, New York, USA, 2Aix-Marseille University, Marseille, France

P647: Is liver steatosis a risk factor for hepatotoxicity in patients with inflammatory bowel disease on thiopruines?ECCO '18 Vienna
Year: 2018
Authors:

J. Phillips1, R. Preskey2*, C. Penfold3, J. Tyrrell-Price1, F. Gordon4

1Bristol Royal Infirmary, Department of Gastroenterology, Bristol, UK, 2Bristol Royal Infirmary, Bristol, UK, 3University of Bristol, School of Clinical Sciences, Bristol, UK, 4Bristol Royal Infirmary, Department of Hepatology, Bristol, UK

P648: Clinical feasibility of dried blood sampling for infliximab in IBD patientsECCO '18 Vienna
Year: 2018
Authors:

S. Berends1,2*, G. D'Haens2, K. Bloem3,4, J. Schaap4, A. De Vries4, T. Rispens3,4, R. Mathôt1

1Academic Medical Center (AMC), Hospital Pharmacy, Amsterdam, The Netherlands, 2Academic Medical Center (AMC), Gastroenterology and Hepatology, Amsterdam, The Netherlands, 3Sanquin Research and Landsteiner Laboratory, Immunopathology, Amsterdam, The Netherlands, 4Sanquin Diagnostic Services, Biologicals Lab, Amsterdam, The Netherlands

P649: Comparison of the KU Leuven ustekinumab concentration assay and the antibodies-to-ustekinumab assay with assays developed at Janssen R&D and used in clinical studies of IBD patientsECCO '18 Vienna
Year: 2018
Authors:

J.C. Marini1, A. Gils2*, G. Shankar1, M. Peeters2, E. Brouwers2, P. van Iperen3, M. Le Bars4, G.S. Bevalander3, B. Sattin5, S. Sloan6

1Janssen Research and Development, LLC, Spring House, PA, USA, 2KU Leuven, Leuven, Belgium, 3Janssen-Cilag BV, Breda, The Netherlands, 4Janssen-Cilag, Issy-les-Moulineaux, France, 5Janssen Inc., Toronto, Canada, 6Janssen Research and Development, LLC, Raritan, NJ, USA

P650: Combination therapy for perianal fistulising Crohn’s disease in biological era: What is the optimal time for surgical intervention?ECCO '18 Vienna
Year: 2018
Authors:

P. Zhu, B.L. Yang*

Affiliated Hospital of Nanjing University of Chinese Medicine, Colon and Rectal Surgery, NANJING, China

P651: Reliability of blood tests, neutrophil lymphocyte ratio (NLR) and Glasgow prognostic index (GPI) to evaluate the severity of the Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

E.O. Gur1*, S. Karaisli1, O.N. Dilek1, T. Acar1, S. Haciyanli1, B. Unsal2, M. Haciyanli1

1Katip Celebi University Ataturk Training and Research Hospital, General Surgery, Izmr, Turkey, 2Katip Celebi University Ataturk Training and Research Hospital, Gastroenterology, Izmr, Turkey

P652: Nutritional adequacy of popular defined diets for inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

N. Nazarenkov1, L. Beeken2, K. Seeger2, A. Ananthakrishnan3, H. Khalili3, J. Lewis4, G. Konijeti2,5*

1University of California, Davis, Davis, USA, 2Scripps Clinic, Division of Gastroenterology, La Jolla, USA, 3Massachusetts General Hospital, Division of Gastroenterology, Boston, USA, 4University of Pennsylvania, Center for Clinical Epidemiology and Biostatistics, Philadelphia, USA, 5The Scripps Research Institute, Scripps Translational Science Institute, La Jolla, USA

P653: Impact of ileostomy on recurrence rate after ileo-colic resection for Crohn’s disease: A critical appraisal from a referral centreECCO '18 Vienna
Year: 2018
Authors:

B. Sensi1, S. D'Ugo1,2*, G. Bagaglini1, A. Di Giorgio1, L. Fazzolari1, G. Sica1

1Tor Vergata University, Department of Surgery, Rome, Italy, 2Tor Vergata University, Surgery, Rome, Italy

P654: Advances in optimalisation of therapeutic drug monitoring using mucosal TNF expression and anti-TNF concentration in patients with inflammatory bowel disease treated with biologicals: Preliminary results from a single-centre studyECCO '18 Vienna
Year: 2018
Authors:

K. Farkas1*, G. Elekes1, D. Kata2, I. Földesi2, S. Lada1, T. Ferenci3, T. Madácsy1, M. Rutka1, A. Bálint1, R. Bor1, A. Fábián1, A. Milassin1, Z. Szepes1, F. Nagy1, J. Maléth1, T. Molnár1

1University of Szeged, 1st Department of Medicine, Szeged, Hungary, 2University of Szeged, Institute of Laboratory Medicine, Szeged, Hungary, 3Physiological Controls Research Center, Óbuda University, Budapest, Hungary

P655: Immunogenicity after transition from adalimumab to ABP 501 in patients with plaque psoriasisECCO '18 Vienna
Year: 2018
Authors:

D. Mytych*, J. Miller, M. Starcevic Manning, I. Wala, H. Wang, N. Zhang, E. Krishnan, A. Kaliyaperumal

Amgen Inc., Biosimilars, Thousand Oaks, USA